Presentation AHA 2016 PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy Presenter: Michael Gibson November 15, 2016
News Conference News AHA 2016 Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI Todd Neale November 14, 2016
News Conference News AHA 2016 AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR Shelley Wood November 09, 2016
Presentation TCT 2016 The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status Presenter: Freek W.A. Verheugt, Pascal Vranckx, Deepak L. Bhatt November 01, 2016
Presentation TCT 2016 The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status Presenter: Freek W.A. Verheugt, Pascal Vranckx, Roxana Mehran November 01, 2016
Presentation TCT 2016 The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status Presenter: Freek W.A. Verheugt, Pascal Vranckx November 01, 2016
Presentation TCT 2016 The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status Presenter: Freek W.A. Verheugt, Pascal Vranckx, C. Michael Gibson November 01, 2016
Presentation TCT 2016 Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI Presenter: David P. Faxon, C. Michael Gibson, Deepak L. Bhatt November 01, 2016
Presentation TCT 2016 When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy? Presenter: David P. Faxon, C. Michael Gibson, Roxana Mehran November 01, 2016
Presentation TCT 2016 Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding Presenter: David P. Faxon, C. Michael Gibson November 01, 2016
Presentation TCT 2016 General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI Presenter: David P. Faxon, C. Michael Gibson, Dominick J. Angiolillo November 01, 2016
Presentation TCT 2016 European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI Presenter: David P. Faxon, C. Michael Gibson, Davide Capodanno November 01, 2016
Presentation TCT 2016 What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt November 01, 2016
Presentation TCT 2016 The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT Presenter: David P. Faxon, C. Michael Gibson, Christopher B. Granger November 01, 2016
Presentation TCT 2016 Editorial perspective: Interventional Treatment of Atrial Fibrillation: Current Strategy and Unmet Needs Presenter: Vivek Y. Reddy October 31, 2016
Presentation TCT 2016 Implantable Thermo-reactive Pulmonary Venous Stent for Atrial Fibrillation (Fulgur) Presenter: Glenn Van Langenhove October 31, 2016
News Daily News Short Bouts of Atrial Tachyarrhythmia Do Not Worsen Prognosis, Study Suggests Todd Neale October 19, 2016
News Daily News Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge Todd Neale October 18, 2016
News Daily News A-fib Screening With Smartphone-Based ECG Feasible, but Clinical Impact Unclear Todd Neale October 13, 2016
News Daily News FDA: ROCKET AF Results Not Affected by Faulty INR Testing in Warfarin Arm Michael O'Riordan October 11, 2016